Source comparison
Comparison: BPC-157 vs Standard Post-Surgical Recovery Protocols
Primary Mechanism FAK-paxillin pathway activation, VEGF upregulation, NO pathway modulation COX enzyme inhibition, broad anti-inflammatory effect Growth factor delivery (PDGF, TGF-β, VEGF) from concentrated platelets BPC-157 targets fibroblast motility and ang
This comparison does not assign a generated winner or score.
- Primary Mechanism
- FAK-paxillin pathway activation, VEGF upregulation, NO pathway modulation
- COX enzyme inhibition, broad anti-inflammatory effect
- Growth factor delivery (PDGF, TGF-β, VEGF) from concentrated platelets
- BPC-157 targets fibroblast motility and angiogenesis; NSAIDs reduce pain but may delay early healing; PRP evidence for ACL is mixed
- Evidence Level
- Preclinical rodent studies; no human RCTs for ACL
- Extensive human data; known to delay bone-tendon healing in some studies
- Mixed clinical evidence; some ACL studies show no benefit, others show modest improvement
- BPC-157 has strongest mechanistic rationale but zero human ACL data
- Typical Dosage
- 10 mcg/kg in rodent models (allometric equivalent ~250–400 mcg daily in humans)
- Ibuprofen 400–800 mg TID, naproxen 500 mg BID
- 3–6 mL injected intra-articularly, 1–3 sessions
- Rodent doses don't map directly; PRP dosing is standardized but outcomes vary
- Timeline to Effect
- 40–60% faster collagen deposition at 14 days in rodent tendons
- Immediate pain relief; potential healing delay if used >7 days post-op
- Variable; some studies show earlier return to activity, others no difference
- BPC-157 shows effect during proliferative phase (days 3–21); NSAIDs affect early inflammation; PRP timing is critical
- Cost
- $50–150/month (research-grade peptide, unregulated market)
- $10–30/month (generic NSAIDs)
- $500–1500 per injection session
- BPC-157 sourcing is unregulated; PRP is costly but insurance may cover in some cases